Last $12.74 USD
Change Today -0.12 / -0.93%
Volume 676.0K
NKTR On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:38 PM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

James Bernad Glavin

Former Director, Nektar Therapeutics
AgeTotal Calculated CompensationThis person is connected to 29 board members in 5 different organizations across 7 different industries.

See Board Relationships
78--

Background*

Mr. James Bernard Glavin, Jim served as Chief Executive Officer of Orchestra Therapeutics, Inc. (Formerly known as Immune Response Corporation) from April 1987 to September 1994, President from October 1987 to September 1994 and its Treasurer from April 1987 to May 1991. From 1983 to 1985, Mr. Glavin served as the Chairman of Genetic Systems Corporation and also served as its President & Chief Executive Officer from 1981 to 1983. Mr. Glavin served as the Chairman of ...

Read Full Background

Corporate Headquarters*

455 Mission Bay Boulevard South
San Francisco, California 94158

United States

Phone: 415-482-5300
Fax: 415-339-5300

Board Members Memberships*

Director
Director
1985-Present
Chairman of The Board of Meridian Fund Inc, Member of Audit Committee, Member of Governance Committee and Member of Qualified Legal Compliance Committee
1985-Present
Chairman of Meridian Fund, Inc and Member of Audit Committee
1993-N/A
Former Director
1997-Present
Director
1999-2005
Former Chairman of the Board
2005-N/A
Former Director and Chairman of Audit Committee

Education*

MBA
Harvard Business School
BS
College of the Holy Cross
Bachelor's Degree
Harvard University

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

There is no Total Compensation data available.
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NKTR:US $12.74 USD -0.12

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Michael W. Aguiar Chief Executive Officer, President and Director
Theravance Inc.
$515.4K
Peter M. Hecht Ph.D. Co-Founder, Chief Executive Officer and Director
Ironwood Pharmaceuticals, Inc.
$100.0K
James A. Schoeneck Chief Executive Officer, President and Director
DepoMed Inc.
$590.6K
Peter S. Greenleaf Chief Executive Officer, Director, Member of Commercialization Committee and Member of Science & Technology Committee
Sucampo Pharmaceuticals, Inc.
--
William J. Polvino M.D.Chief Executive Officer and President
Veloxis Pharmaceuticals A/S
--
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEKTAR THERAPEUTICS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.